Clinical Features of Polypoidal Choroidal Vasculopathy and Visual Outcomes in the Absence of Classic Choroidal Neovascularization

2010 ◽  
Vol 224 (3) ◽  
pp. 147-152 ◽  
Author(s):  
Seijo Yamaoka ◽  
Annabelle A. Okada ◽  
Michitaka Sugahara ◽  
Tetsuo Hida
2021 ◽  
Vol Volume 15 ◽  
pp. 3557-3562
Author(s):  
Yu Matsuo ◽  
Masatoshi Haruta ◽  
Yumi Ishibashi ◽  
Koki Ishibashi ◽  
Kei Furushima ◽  
...  

2018 ◽  
Vol 46 (8) ◽  
pp. 916-925 ◽  
Author(s):  
Hyun Goo Kang ◽  
Hyunseung Kang ◽  
Suk Ho Byeon ◽  
Sung Soo Kim ◽  
Hyoung Jun Koh ◽  
...  

2009 ◽  
Vol 53 (6) ◽  
pp. 588-592 ◽  
Author(s):  
Mitsuhiro Imasawa ◽  
Toyoaki Tsumura ◽  
Arata Sekine ◽  
Toyohiko Kikuchi ◽  
Hiroyuki Iijima

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Hyungwoo Lee ◽  
Minsu Jang ◽  
Hyung Chan Kim ◽  
Hyewon Chung

AbstractWe investigated the association of visual outcome in typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) with or without pachychoroid with lesion areas on optical coherence tomography (OCT) quantified by convolutional neural network (CNN) analysis. Treatment-naïve 132 nAMD and 45 PCV eyes treated with ranibizumab or aflibercept for at least 12 months were retrospectively reviewed. Significant factors, including intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED) and subretinal hyperreflective material (SHRM) area quantified by CNN at baseline and 12 months, were analyzed by logistic regression analyses for 3-line visual gain or maintenance of 20/30 Snellen vision. Visual gain at the final visit in nAMD was associated with a smaller SHRM at baseline (OR 0.167, P = 0.03), greater decrease in SRF and SHRM from baseline to month 12 (OR 1.564, P = 0.02; OR 12.877, P = 0.01, respectively). Visual gain in nAMD without pachychoroid was associated with a greater decrease in SRF and SHRM (OR 1.574, P = 0.03, OR 1.775, P = 0.04). No association was found in nAMD with pachychoroid and any type of PCV. Greater decrease in SRF and SHRM from baseline to month 12 was associated with favorable visual outcomes in nAMD without pachychoroid but not in nAMD with pachychoroid and PCV.


Sign in / Sign up

Export Citation Format

Share Document